Potent bisphosphonate therapy for preventing fractures after denosumab discontinuation in osteoporosis
Background: Denosumab cessation causes rebound bone turnover, fast bone loss, and an elevated risk of vertebral fractures. Pooled data about the fracture prevention efficacy of potent bisphosphonates (BPs) as sequential therapy have been lacking to counteract this risk. Methods: This systematic review and meta-analysis...